Abstract:Puerarin (8-β-D-glucopyranosyl-7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one) is a major pharmacological component of Puerariae Radix, the root of Pueraria lobata. We investigated the effect of puerarin on hepatic cytochrome P450-mediated drug metabolism in rats and humans. The in vitro cytochrome P450 inhibitory effect of puerarin in human and rat liver microsomes was evaluated using the following model cytochrome P450 substrates: phenacetin for CYP1A, diclofenac for CYP2C, dextromethorphan for CYP2D, and testosterone for CYP3A. The in vivo pharmacokinetics of intravenous and oral buspirone, a probe substrate for CYP3A, was studied with single simultaneous intravenous coadministration of puerarin in rats. In the in vitro cytochrome P450 inhibition study, the rate of disappearance of testosterone was significantly reduced in the presence of 10 µM PU, while that of other cytochrome P450 substrates was not significantly affected in both human and rat liver microsomes, suggesting that puerarin inhibits the in vitro hepatic CYP3A-mediated metabolism in the human and rat systems (IC50 = 15.5 ± 3.9 µM). After intravenous administration of buspirone with single simultaneous coadministration of intravenous puerarin at a dose of 10 mg/kg in rats, the total area under the plasma concentration-time curve from time zero to time infinity was increased while time-averaged total body clearance decreased. When buspirone was orally administered in rats with the 10 mg/kg intravenous puerarin coadministration, both total area under the plasma concentration-time curve from time zero to time infinity and the extent of absolute oral bioavailability were significantly increased. Therefore, results of the in vitro microsomal and in vivo pharmacokinetic studies suggest the possible inhibition of hepatic CYP3A-mediated drug metabolism by puerarin administration, potentially leading to metabolism-mediated herb-drug interactions with clinical significance.

Exploring adverse effects of puerarin on catalase by multiple spectroscopic investigations and docking studies in vitro

Puerarin Protects Differentiated Pc12 Cells from H2o2-Induced Apoptosis Through the Pi3k/Akt Signalling Pathway

THE MYOCARDIAL PROTECTIVE EFFECTS OF PUERARIN ON STZ-INDUCED DIABETIC RATS

The Study of Anti-Metabolic Syndrome Effect of Puerarin in Vitro

Radical Scavenging Activity of Puerarin: A Theoretical Study

Protective Effect of Puerarin Form the Roots of Pueraria Lobata Against Systemic Inflammatory Response Syndrome by Regulating the Levels of Related Cytokines

Role of the interaction between puerarin and the erythrocyte membrane in puerarin-induced hemolysis

Puerarin protects against acetaminophen‐induced oxidative damage in liver through activation of the Keap1/Nrf2 signaling pathway

Anti-Inflammatory and Anti-oxidative Effects of Puerarin in Postmenopausal Cardioprotection: Roles of Akt and Heme Oxygenase-1

Safety Evaluation and Antihyperlipidemia Effect of Aqueous Extracts from Fermented Puerh Tea

Protective effects of puerarin on metabolic diseases: Emphasis on the therapeutical effects and the underlying molecular mechanisms

Puerarin attenuates cadmium-induced hepatic lipid metabolism disorder by inhibiting oxidative stress and inflammation in mice

Puerarin protects against high glucose-induced acute vascular dysfunction: Role of heme oxygenase-1 in rat thoracic aorta

Puerarin protects endothelial cells from oxidized low density lipoprotein induced injuries via the suppression of LOX-1 and induction of eNOS

In Vitro and In Vivo Evaluation of the Effect of Puerarin on Hepatic Cytochrome P450-Mediated Drug Metabolism

Puerarin: a hepatoprotective drug from bench to bedside

Hepatoprotective activity of puerarin against carbon tetrachloride-induced injuries in rats: a randomized controlled trial

The Effects of Puerarin on Rat Ventricular Myocytes and the Potential Mechanism

Study on effect of different combinations of traditional Chinese medicine preparation active parts on metabolism of puerarin in plasma of rats

[Effect of Puerarin on platelet activating factors CD63 and CD62P, plasminogen activator inhibitor and C-reactive protein in patients with unstable angia pectoris]

Effects of puerarin on the pharmacokinetics of astragaloside IV in rats and its potential mechanism